Genetic risk score for coronary artery calcification predicts coronary artery disease beyond traditional risk factors - Mishra, Pashupati P.; Mishra, Binisha H.; Lyytikäinen, Leo-Pekka; Goebeler, Sirkka; Martiskainen, Mika; Hakamaa, Emma; Kleber, Marcus E.; Delgado, Graciela E.; März, Winfried; Kähönen, Mika; Karhunen, Pekka J.; Lehtimäki, Terho (medRxiv, 2024)
Aim The modest added predictive value of the existing genetic risk scores (GRSs) for coronary artery disease (CAD) could be partly due to missing genetic components, hidden in the genetic architecture of intermediate phenotypes such as coronary artery calcification (CAC). In this study, we investigated the predictive ability of CAC GRS for CAD.Materials and methods We investigated the association of CAC GRSs with CAD and coronary calcification among the participants in the Ludwigshafen Risk and Cardiovascular Health study (LURIC) (n=2742), the Tampere Vascular Study (TVS) (n=133), and the Tampere Sudden Death Study (TSDS) (n=660) using summary data from the largest multi-ancestry GWAS meta-analysis of CAC to date. Added predictive value of the CAC GRS over the traditional CVD risk factors was tested with standard train–test machine learning approach using the LURIC data, which had the largest sample size.Results CAC GRS was significantly associated with CAD in LURIC (OR=1.41, 95% CI [1.28–1.55]), TVS (OR=1.79, 95% CI [1.05–3.21]) as well as in TSDS (OR=4.20, 95% CI [1.74–10.52]). CAC GRS showed strong association with calcification areas in left (OR=1.78, 95% CI [1.16-2.74]) and right (OR=1.71, 95% CI [1.98-2.67]) coronary arteries. In addition, there was statistically significant added predictive value of the CAC GRS for CAD over the used traditional CVD risk factors (AUC 0.734 vs 0.717, p-value = 0.02).Conclusions This study showed that CAC GRS is a new risk marker for CAD in three European cohorts, with added predictive value over the traditional CVD risk factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Academy of Finland (Grant number: 349708 for P.P.M and 322098 for T.L). Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital (grants X51001 and X51401); Juho Vainio Foundation; Finnish Foundation for Cardiovascular Research; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjo Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); Tampere University Hospital Supporting Foundation, Finnish Society of Clinical Chemistry and Jane and Aatos Erkko Foundation. LURIC was supported by the 7th Framework Programs Atheroremo (Grant Agreement number 201668) and RiskyCAD (grant agreement number 305739) of the European Union and by the H2020 Programs TO_AITION (grant agreement number 848146) and TIMELY (grant agreement number 101017424) of the European Union.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee of the Landesarztekammer Rheinland-Pfalz [#837.255.97(1394)].I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.